Abstract
Objective To analyze the relationship between the expression of CD151 and ERK1 and invasion and metastasis of gastric adenocarcinoma, and in order to provide reference for the evaluation of the disease and prognosis. Methods The expression of CD151 and ERK1 in forty-eight cases of gastric adenocarcinoma and adjacent tissues were detected by immunohistochemistry, the relationship between positive expression of CD151 and ERK1 and clinicopathological features was analyzed; the relationship between the expression of CD151 and ERK1 protein and prognosis of the patients was analyzed. Results The positive rates of CD151 and ERK1 in gastric adenocarcinoma tissues were 64.58%(31/48) and 56.25%(27/48), which were significantly higher than those of adjacent tissues 10.42% (5/48) and 16.67% (8/48), the differences were statistically significant (χ2=30.044, 16.232, P=0.000, 0.000); the positive rates of CD151 and ERK1 in TNM stage III±IV, lymph node metastasis, invasion to the serosa and poorly differentiated patients were significantly higher than those in Ⅰ-Ⅱ, non-lymph node metastasis, non-invasion to the serosa and medium and high differentiated patients, the differences were statistically significant (χ2=4.697, 9.952, 7.288, 5.923, P=0.030, 0.002, 0.007, 0.031)(χ2=5.000, 6.527, 9.257, 6.647, P=0.025, 0.011, 0.002, 0.036); the patients were followed up to July 2017, the survival rates of CD151 and ERK1 protein positive patients were lower than those of CD151 and ERK1 protein negative patients, the differences were statistically significant (χ2=4.373, 6.032, P=0.036, 0.014). Conclusion The expression of CD151 and ERK1 protein in gastric adenocarcinoma tissues is significantly higher, and is closely related to lymph node metastasis, invasion depth, clinical stage and prognosis.It can be used as an important index to evaluate invasion, metastasis and prognosis of patients with gastric adenocarcinoma. Key words: Gastric adenocarcinoma; CD151; ERK1; invasion and metastasis
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
